| scholarly article | Q13442814 |
| P50 | author | Anke Witting | Q67390353 |
| P. Weydt | Q67390356 | ||
| Soyon Hong | Q80184031 | ||
| P2093 | author name string | Michel Kliot | |
| Nephi Stella | |||
| Thomas Moller | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | endocannabinoids | Q10483908 |
| P304 | page(s) | 1555-1557 | |
| P577 | publication date | 2004-06-01 | |
| P1433 | published in | Journal of Neurochemistry | Q6295643 |
| P1476 | title | Endocannabinoids accumulate in spinal cord of SOD1 G93A transgenic mice | |
| P478 | volume | 89 |
| Q38013238 | ALSUntangled No. 16: cannabis |
| Q45943797 | Abnormal sensitivity of cannabinoid CB1 receptors in the striatum of mice with experimental amyotrophic lateral sclerosis. |
| Q37709583 | Altered presymptomatic AMPA and cannabinoid receptor trafficking in motor neurons of ALS model mice: implications for excitotoxicity. |
| Q36591816 | An optimized GC-MS method detects nanomolar amounts of anandamide in mouse brain |
| Q48242279 | Analysis of endocannabinoid receptors and enzymes in the post-mortem motor cortex and spinal cord of amyotrophic lateral sclerosis patients. |
| Q35897353 | Cannabinoid signaling in glial cells |
| Q91934280 | Cannabinoids and the expanded endocannabinoid system in neurological disorders |
| Q37264965 | Cannabinoids as therapeutic agents for ablating neuroinflammatory disease |
| Q38563981 | Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications |
| Q46720336 | Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival. |
| Q43075467 | Cannabis and amyotrophic lateral sclerosis: hypothetical and practical applications, and a call for clinical trials. |
| Q37637769 | Changes in CB(1) and CB(2) receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias |
| Q39215660 | Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1(G93A) transgenic mice and evaluation of a Sativex(®) -like combination of phytocannabinoids: interest for future therapies in amyotrophic lateral sclerosis. |
| Q38395012 | Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders |
| Q26777929 | Complementary and Alternative Therapies in Amyotrophic Lateral Sclerosis |
| Q80229284 | Dosing medical marijuana: rational guidelines on trial in Washington State |
| Q34477695 | Early endogenous activation of CB1 and CB2 receptors after spinal cord injury is a protective response involved in spontaneous recovery. |
| Q37250243 | Endocannabinoid signaling in microglial cells |
| Q28267822 | Endocannabinoids in Multiple Sclerosis and Amyotrophic Lateral Sclerosis |
| Q38715276 | Essential Dietary Bioactive Lipids in Neuroinflammatory Diseases |
| Q34597537 | Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection |
| Q46639969 | Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. |
| Q38684679 | Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation |
| Q38996589 | Pros and Cons of Medical Cannabis use by People with Chronic Brain Disorders |
| Q36967863 | Role of cannabinoids and endocannabinoids in cerebral ischemia |
| Q35172127 | Semaphorins in axon regeneration: developmental guidance molecules gone wrong? |
| Q35600288 | Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic pain. |
| Q39624887 | TBC2health: a database of experimentally validated health-beneficial effects of tea bioactive compounds. |
| Q88160617 | Targeting glial cannabinoid CB2 receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis |
| Q36902277 | The (endo)cannabinoid system in multiple sclerosis and amyotrophic lateral sclerosis |
| Q24650098 | The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset |
| Q34098196 | The endocannabinoid system as a target for the treatment of neurodegenerative disease |
| Q37709370 | The endocannabinoid system as a target for the treatment of neuronal damage |
| Q48097673 | The endocannabinoid system in canine Steroid-Responsive Meningitis-Arteritis and Intraspinal Spirocercosis |
| Q36381416 | The endocannabinoid system: current pharmacological research and therapeutic possibilities |
| Q36341688 | The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids |
Search more.